NCT03157128 2026-04-16LIBRETTO-001Eli Lilly and CompanyPhase 1/2 Active not recruiting857 enrolled 24 charts 6 FDA
NCT07185997 2026-04-16Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon MutationsArriVent BioPharma, Inc.Phase 3 Recruiting480 enrolled
NCT03803787 2026-04-08Prophylactic Inhaled Steroids to Reduce Radiation Pneumonitis Frequency and Severity in Lung Cancer PatientsInstituto Nacional de Cancerologia de MexicoPhase 2 Recruiting72 enrolled
NCT05462717 2026-04-08Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid TumorsRevolution Medicines, Inc.Phase 1 Active not recruiting222 enrolled
NCT03093116 2026-04-03TRIDENT-1Turning Point Therapeutics, Inc.Phase 1/2 Recruiting500 enrolled 5 FDA